Activity Provided By:

Amedco LLC and CancerNet LLC.

Current and Emerging Treatment Options for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Carcinoma)

Overview / Abstract:	Target Audience This activity is designed to meet the educational needs of medical oncologists, urologists, radiation oncologists, nurse practitioners, physician assistants, nurses, pharmacists on the latest advances in the diagnosis, and treatment of genitourinary cancers (prostate cancer, renal cell carcinoma and urothelial carcinoma). Program Overview This virtual live webcast will cover topics on the diagnosis, treatment, and management of patients with genitourinary cancers (prostate cancer, renal cell carcinoma and urothelial carcinoma). Learning Objectives Upon completion of this activity, participants should be better able to: Appraise the efficacy and safety of novel combinations of ADT and androgen axis inhibitors in patients with prostate cancer Assess sequential treatment strategies and combination therapies for renal cell carcinoma (RCC) with multitargeted kinase inhibitors Evaluate immunotherapy options with PD-1/PD-L1 checkpoint inhibitors and targeted therapy combinations in the treatment of RCC Outline the immunotherapy and antibody-drug conjugate based therapies for urothelial carcinoma
Expiration	Jun 17, 2021
Discipline(s)	Nursing CNE, Pharmacy CPE, Physician CME
Format	Online
Credits / Hours	2.0 AMA PRA Category 1 Credit(s)™
Accreditation	ACCME
Presenters / Authors / Faculty	Faculty Nizar M. Tannir, MD Nizar M. Tannir, MD Professor and Chair ad interim, Ransom Horne, Jr. Professor in Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, UT MD Anderson Cancer Center, Houston, TX Robert Motzer, MD Robert Motzer, MD Attending Physician, Memorial Sloan-Kettering Cancer Center, Professor of Medicine, Weill Medical College of Cornell University, New York, NY Amado J Zurita, MD Amado J Zurita, MD Associate Professor of Medicine, MD Anderson Cancer Center, Department of Genitourinary Medical Oncology \| Division of Cancer Medicine, Houston, TX Joaquim Bellmunt, MD, PhD Joaquim Bellmunt, MD, PhD Director, Bladder Cancer Program, Beth Israel Deaconess Medical Center, Associate Professor of Medicine, Harvard Medical School, Boston, MA
Sponsors / Supporters / Grant Providers	Bristol-Myers Squibb, Merck Sharp & Dohme Corp. and Eisai, Inc.
Keywords / Search Terms	Relias LLC Relias LLC., FREE CME., Cancer Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map